<DOC>
	<DOC>NCT01553279</DOC>
	<brief_summary>Primary objective • To evaluate the concomitant administration of PR5I with two types of MCC vaccines (MCC-TT and MCC-CRM) Secondary objectives Part I - To describe the immunogenicity of PR5I when PR5I is given at 2 months of age and concomitantly with MCC vaccines at 3 and 4 months of age - To describe the immunogenicity of MCC vaccines when MCC vaccines are given concomitantly with PR5I at 3 and 4 months of age (post-dose 1 and post-dose 2) - To describe the safety of PR5I given concomitantly with PCV-13 and MCC vaccines Part II • To describe the immunogenicity and safety of Hib-MCC when given at 12 months of age in subjects who have received PR5I at 2, 3 and 4 months of age</brief_summary>
	<brief_title>Immunogenicity and Safety of V419 Given at 2, 3 and 4 Months of Age With Meningococcal Serogroup C Conjugate Vaccines</brief_title>
	<detailed_description />
	<mesh_term>Bacterial Infections</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Healthy infant 46 to 74 days of age (both inclusive) Parent(s)/legal representative able to comply will the study procedures Subject participating in a study with an investigational compound or device since birth History of congenital or acquired immunodeficiency History of leukemia, lymphoma, malignant melanoma or myeloproliferative disorder Chronic illness that could interfere with study conduct or completion Hypersensitivity to any of the vaccines components or history of a lifethreatening reaction to a vaccine containing the same substances as the study vaccines or contraindication to any of the study vaccines History or mother history of HBsAg seropositivity Coagulation disorder that contraindicate intramuscular injection History of vaccination with a hepatitis B, Haemophilus influenzae type b conjugate, diphtheria, tetanus, pertussis (acellular or wholecell), poliovirus, pneumococcal conjugate or polysaccharide, meningococcal serogroup C conjugate, measles, mumps, or rubella containing vaccine(s) History of hepatitis B, Haemophilus influenzae type b, diphtheria, tetanus, pertussis, poliomyelitis, invasive pneumococcal, meningococcal serogroup C, measles, mumps or rubella infection Receipt of immune globulin, blood or bloodderived products, immunosuppressive agents systemic corticosteroids since birth Vaccination with an inactivated (except influenza vaccine) or conjugated or live vaccine in the last 30 days or vaccination with an inactivated influenza vaccine in the last 14 days Antipyretic, analgesic and nonsteroidal antiinflammatory medications in the last 48 hours Febrile illness or body temperature ≥38.0°C in the last 24 hours</criteria>
	<gender>All</gender>
	<minimum_age>46 Days</minimum_age>
	<maximum_age>74 Days</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>